Citations

Showing 10 of 108104 citations.

The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
Stanković, Iva , Vignatelli, Luca , Fanciulli, Alessandra , Calandra–Buonaura, Giovanna , Seppi, Klaus , Palma, Jose‐Alberto , Meissner, Wassilios G. , Krismer, Florian , Berg, Daniela , Halliday, Glenda M. , Ling, Helen , Low, Phillip A. , Panicker, Jalesh N. , Pellecchia, Maria Teresa , Quinn, Niall , Stamelou, María , Tolosa, Eduardo , Warner, Tom, Stankovic, Iva , Vignatelli, Luca , Fanciulli, Alessandra , Seppi, Klaus , Palma, Jose-Alberto , Meissner, Wassilios G , Krismer, Florian , Cortelli, Pietro , Halliday, Glenda , Höglinger, Günter U , Ling, Helen , Sakakibara, Ryuji , Stamelou, Maria , Kaufmann, Horacio , Pellecchia, Maria Teresa , Wenning, Gregor K. , Cortelli, Pietro , Freeman, Roy L. , Höglinger, Günter U. , Lang, Anthony E. , Litvan, Irene , Miki, Yasuo , Sakakibara, Ryuji , Tsuji, Shoji , Warner, Tom, Poewe, Werner H

Mayo Clinic

Movement Disorders | April 21, 2022 | Volume: 37 | Issue: 6 | Pages: 1131-1148

10.1002/mds.29005 | PMID 35445419 Get It

ABSTRACT Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. Objective To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence‐based and consensus‐based methodology. Methods We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference. Results The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow. Conclusions This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Central Nervous System Metabolism in Autism, Epilepsy and Developmental Delays: A Cerebrospinal Fluid Analysis
Brister, Danielle , Werner, Brianna, Gideon, Geoffrey, McCarty, Patrick J. , Lane, Alison L., Burrows, Brian T., McLees, Sallie E., Adelson, P. David , Arango, Jorge , Marsh, W., Flores, Angelea, Ly, Ngoc Han, Flood, Madison, Brown, Danni, Carpentieri, David , Jin, Yan , Gu, Haiwei , Frye, Richard E. , Marsh, William, Carpentieri, David , Frye, Richard E , Pankratz, Matthew T

Mayo Clinic

Metabolites | April 21, 2022 | Volume: 12 | Issue: 5 | Pages: 371

10.3390/metabo12050371 | PMID 35629876 Get It

Neurodevelopmental disorders are associated with metabolic pathway imbalances; however, most metabolic measurements are made peripherally, leaving central metabolic disturbances under-investigated. Cerebrospinal fluid obtained intraoperatively from children with autism spectrum disorder (ASD, n = 34), developmental delays (DD, n = 20), and those without known DD/ASD (n = 34) was analyzed using large-scale targeted mass spectrometry. Eighteen also had epilepsy (EPI). Metabolites significantly related to ASD, DD and EPI were identified by linear models and entered into metabolite–metabolite network pathway analysis. Common disrupted pathways were analyzed for each group of interest. Central metabolites most involved in metabolic pathways were L-cysteine, adenine, and dodecanoic acid for ASD; nicotinamide adenine dinucleotide phosphate, L-aspartic acid, and glycine for EPI; and adenosine triphosphate, L-glutamine, ornithine, L-arginine, L-lysine, citrulline, and L-homoserine for DD. Amino acid and energy metabolism pathways were most disrupted in all disorders, but the source of the disruption was different for each disorder. Disruption in vitamin and one-carbon metabolism was associated with DD and EPI, lipid pathway disruption was associated with EPI and redox metabolism disruption was related to ASD. Two microbiome metabolites were also detected in the CSF: shikimic and cis-cis-muconic acid. Overall, this study provides increased insight into unique metabolic disruptions in distinct but overlapping neurodevelopmental disorders.
Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing
Wang, Jeremy , Bhakta, Nickhill , Miller, Vanessa Ayer , Revsine, Mahler, Litzow, Mark R. , Paietta, Elisabeth, Fedoriw, Yuri, Roberts, Kathryn G., Gu, Zhaohui , Mullighan, Charles G. , Jones, Corbin D. , Ayer Miller, Vanessa , Alexander, Thomas B , Mullighan, Charles G , Wang, Jeremy R , Bhakta, Nickhill , Revsine, Mahler, Litzow, Mark R. , Paietta, Elisabeth, Fedoriw, Yuri, Roberts, Kathryn G., Gu, Zhaohui , Jones, Corbin D.

Mayo Clinic

JCO Precision Oncology | April 20, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00326 | PMID 35442720 Get It

PURPOSE Most cases of pediatric acute leukemia occur in low- and middle-income countries, where health centers lack the tools required for accurate diagnosis and disease classification. Recent research shows the robustness of using unbiased short-read RNA sequencing to classify genomic subtypes of acute leukemia. Compared with short-read sequencing, nanopore sequencing has low capital and consumable costs, making it suitable for use in locations with limited health infrastructure. MATERIALS AND METHODS We show the feasibility of nanopore mRNA sequencing on 134 cryopreserved acute leukemia specimens (26 acute myeloid leukemia [AML], 73 B-lineage acute lymphoblastic leukemia [B-ALL], 34 T-lineage acute lymphoblastic leukemia, and one acute undifferentiated leukemia). Using multiple library preparation approaches, we generated long-read transcripts for each sample. We developed a novel composite classification approach to predict acute leukemia lineage and major B-ALL and AML molecular subtypes directly from gene expression profiles. RESULTS We demonstrate accurate classification of acute leukemia samples into AML, B-ALL, or T-lineage acute lymphoblastic leukemia (96.2% of cases are classifiable with a probability of > 0.8, with 100% accuracy) and further classification into clinically actionable genomic subtypes using shallow RNA nanopore sequencing, with 96.2% accuracy for major AML subtypes and 94.1% accuracy for major B-lineage acute lymphoblastic leukemia subtypes. CONCLUSION Transcriptional profiling of acute leukemia samples using nanopore technology for diagnostic classification is feasible and accurate, which has the potential to improve the accuracy of cancer diagnosis in low-resource settings.
Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis
Blum, Karni, Tiosano, Alon , Lotan, Itay , Hellmann, Mark A. , Wilf‐Yarkoni, Adi , Bialer, Omer , Pittock, Sean J. , Bhatti, M. Tariq, Schmitz‐Hübsch, Tanja , Friedemann, Paul, Chen, John J. , Pittock, S J , Chen, John J , Lotan, Itay , Stiebel‐Kalish, Hadas , Rubarth, Kerstin , Flanagan, Eoin P. , Asseyer, Susanna

Mayo Clinic

No container title available | April 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1411863/v2 Get It

Abstract Background: Optic neuritis (ON) is a frequent presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-antibody disease (MOGAD) at onset. The pathophysiology underlying these diseases, especially MOGAD, is still being elucidated. While obesity has been reported to potentially be a risk factor for MS, this has not been explored in NMOSD or MOGAD. We aimed to investigate a possible association between obesity (body mass index [BMI] >30 kg/m²) and patients with MOGAD, NMOSD or MS. Methods: Multicenter non-interventional retrospective data collection from a first ever demyelinating attack of ON in patients subsequently diagnosed with MOGAD, NMOSD or MS between 2005-2020. The following data was collected: age, gender, ethnicity, BMI at disease onset and the etiology of ON after diagnostic work-up. A mixed model analysis was performed to assess the ability of obesity or BMI to predict MOGAD-ON and distinguish MOGAD-ON from NMOSD- and MS-ON. Main outcome measures included BMI in patients with acute ON and subsequent diagnosis of MOGAD, NMOSD or MS. Results: One-hundred and eighty-three patients were included: 44 with MOGAD, 49 with NMOSD, and 90 with MS. A higher BMI was significantly associated with a diagnosis of MOGAD-ON (p<0.001); in MOGAD patients the mean BMI was 31.6 kg/m² (standard deviation (SD) 7.2), while the mean BMI was 24.7 kg/m² (SD 5.3) in NMOSD patients and 26.9 kg/m² (SD 6.2) in MS patients. Mixed effects multionimal logistic regression, adjusted for age and gender with obesity as a binary variable revealed that obesity was associated with a higher odds ratio (OR) of a subsequent MOGAD diagnosis (OR 5.466, 95% CI: [2.039, 14.650], p = 0.001) in contradistinction with NMOSD. Conclusion: This study suggests an association between obesity and MOGAD. Our finding requires further exploration, but could have significant pathophysiologic implications if confirmed in larger prospective studies.
Increasing Incidence of Early-Onset Colorectal Cancer
Sinicrope, Frank A. , Sinicrope, Frank A

Mayo Clinic

New England Journal of Medicine | April 20, 2022 | Volume: 386 | Issue: 16 | Pages: 1547-1558

10.1056/nejmra2200869 | PMID 35443109 Get It

GPU‐accelerated Monte Carlo‐based online adaptive proton therapy: A feasibility study
Feng, Hongying , Patel, Samir H. , Wong, William W. , Younkin, James E. , Penoncello, Gregory P. , Morales, Danairis Hernandez, Stoker, J. , Robertson, Daniel , Fatyga, M., Foote, Robert L. , Stoker, Joshua B., Robertson, Daniel G, Fatyga, Mirek, Bues, Martin , Schild, Steven E. , Penoncello, Gregory , Liu, Wei

Mayo Clinic

Medical Physics | April 20, 2022 | Volume: 49 | Issue: 6 | Pages: 3550-3563

10.1002/mp.15678 | PMID 35443080 Get It

AbstractPurposeTo develop an online graphic processing unit (GPU)‐accelerated Monte Carlo‐based adaptive radiation therapy (ART) workflow for pencil beam scanning (PBS) proton therapy to address interfraction anatomical changes in patients treated with PBS.Methods and MaterialsA four‐step workflow was developed using our in‐house developed GPU‐accelerated Monte Carlo‐based treatment planning system to implement online Monte Carlo‐based ART for PBS. The first step conducts diffeomorphic demon‐based deformable image registration (DIR) to propagate contours on the initial planning CT (pCT) to the verification CT (vCT) to form a new structure set. The second step performs forward dose calculation of the initial plan on the vCT with the propagated contours after manual approval (possible modifications involved). The third step triggers a reoptimization of the plan depending on whether the verification dose meets the clinical requirements or not. A robust evaluation will be done for both the verification plan in the second step and the reopotimized plan in the third step. The fourth step involves a two‐stage (before and after delivery) patient‐specific quality assurance (PSQA) of the reoptimized plan. The before‐delivery PSQA is to compare the plan dose to the dose calculated using an independent fast open‐source Monte Carlo code, MCsquare. The after‐delivery PSQA is to compare the plan dose to the dose recalculated using the log file (spot MU, spot position, and spot energy) collected during the delivery. Jaccard index (JI), dice similarity coefficients (DSCs), and Hausdorff distance (HD) were used to assess the quality of the propagated contours in the first step. A commercial plan evaluation software, ClearCheck™, was integrated into the workflow to carry out efficient plan evaluation. 3D Gamma analysis was used during the fourth step to ensure the accuracy of the plan dose from reoptimization. Three patients with three different disease sites were chosen to evaluate the feasibility of the online ART workflow for PBS.ResultsFor all three patients, the propagated contours were found to have good volume conformance [JI (lowest‐highest: 0.833–0.983) and DSC (0.909–0.992)] but suboptimal boundary coincidence [HD (2.37–20.76 mm)] for organs‐at‐risk. The verification dose evaluated by ClearCheck™ showed significant degradation of the target coverage due to the interfractional anatomical changes. Reoptimization on the vCT resulted in great improvement of the plan quality to a clinically acceptable level. 3D Gamma analyses of PSQA confirmed the accuracy of the plan dose before delivery (mean Gamma index = 98.74% with a threshold of 2%/2 mm/10%), and after delivery based on the log files (mean Gamma index = 99.05% with a threshold of 2%/2 mm/10%). The average time cost for the complete execution of the workflow was around 858 s, excluding the time for manual intervention.ConclusionThe proposed online ART workflow for PBS was demonstrated to be efficient and effective by generating a reoptimized plan that significantly improved the plan quality.
Persistent Methicillin-Susceptible Bacteremia Rapidly Cleared with Cefazolin and Ertapenem Combination Therapy in a Patient with COVID-19
Ilges, Dan , Krishnan, Gayathri , Ilges, Dan , Geng, Elvin Hsing

Mayo Clinic

Case Reports in Infectious Diseases | April 20, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-5

10.1155/2022/6828538 | PMID 35462678 Get It

Methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSIs) are associated with significant morbidity and mortality. MSSA BSIs can rapidly disseminate, resulting in deep-seated infections, prolonged durations of bacteremia, and further metastases. Recently, cefazolin and ertapenem combination therapy has emerged as a potential therapeutic strategy to sterilize the blood in patients with persistent MSSA bacteremia. Here, we present a patient with COVID-19 pneumonia and concomitant MSSA BSI achieving blood culture sterilization within 24 hours of cefazolin and ertapenem combination therapy initiation following 11 days of positive blood cultures.
The Effect of Diabetes-Associated Variation in TCF7L2 on Postprandial Glucose Metabolism When Glucagon and Insulin Concentrations Are Matched
Adams, J.D. , LAURENTI, MARCELLO C. , Wismayer, Daniel Schembri, Bailey, Kent R. , Man, Chiara Dalla , Vella, Adrian , Adams, Jon D, Egan, Aoife M. , Schembri Wismayer, Daniel, Vella, Adrian , Dalla Man, Chiara , Cobelli, Claudio

Mayo Clinic

Metabolic Syndrome and Related Disorders | April 20, 2022 | Volume: 20 | Issue: 6 | Pages: 329-335

10.1089/met.2021.0136 | PMID 35442800 Get It

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Li, Maggie , Beck, Evan J. , Laeyendecker, Oliver , Eby, Yolanda , Wouters, Camille, Chiklis, Gregory R., Block, William , McKie, Robert O., Joyner, Michael J. , Wiltshire, Timothy D. , Dietz, Allan B. , Gniadek, Thomas J. , Shapiro, Arell, Yarava, Anusha , Lane, Karen , Bloch, Evan M. , Cachay, Edward R. , Huamán, Moisés A. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Gerber, Jonathan M. , Sullivan, David , Wiltshire, Timothy D , Dietz, Allan B , Hanley, Daniel F , Bloch, Evan M , Shoham, Shmuel , Cachay, Edward R , Huaman, Moises A , Levine, Adam C , Paxton, James H , Gerber, Jonathan M , Gebo, Kelly A , Casadevall, Arturo , Sullivan, David J , Joyner, Michael J , Laeyendecker, Oliver , Tobian, Aaron A.R. , Caturegli, Patrizio , Block, William, Hanley, Daniel F. , Shoham, Shmuel , Meisenberg, Barry R. , Anjan, Shweta , Casadevall, Arturo , Pekosz, Andrew

Mayo Clinic

Blood Advances | April 20, 2022 | Volume: 6 | Issue: 12 | Pages: 3678-3683

10.1182/bloodadvances.2022007410 | PMID 35443020 Get It

Abstract The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-δ/pre-ο donor units obtained before March 2021, 20 post-δ COVID-19/postvaccination units, and 1 pre-δ/pre-ο hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], δ, and ο) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to δ or ο, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-δ COVID-19/postvaccination units and the hyperimmunoglobulin effectively neutralized all 3 variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.
Closing the Brief Case: Sister Fungi in a Patient with AIDS
Misra, Anisha , Roiko, Marijo S. , Saleh, Omar Abu , Morris, Heather, Pritt, Bobbi S. , Roiko, Marijo , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | April 20, 2022 | Volume: 60 | Issue: 4 | Pages: No page available

10.1128/jcm.01147-21 | PMID 35442075 Get It